Ghost Tree Capital’s Celldex Therapeutics CLDX Stock Holding History

Ghost Tree Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-300,000	Closed	-$8.71M	–	37
2022 Q1	$10.2M	Sell	300,000 -50,000	-14%	-$1.6M	2.22%	9
2021 Q4	$13.5M	Buy	350,000 +95,000	+37%	+$4.14M	4.85%	4
2021 Q3	$13.8M	Sell	255,000 -30,000	-11%	-$1.41M	4.03%	4
2021 Q2	$9.53M	Buy	285,000 +35,000	+14%	+$961K	2.62%	13
2021 Q1	$5.15M	Buy	+250,000	New	+$5.74M	1.21%	25

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ghost Tree Capital's CLDX Position: Q2 2022 in Review

Ghost Tree Capital sold out of Celldex Therapeutics (CLDX) in Q2 2022, closing a stake of 300,000 shares — an estimated $8.71M sold.

Ghost Tree Capital first reported a position in CLDX in Q1 2021 and held it in 5 quarters. The position peaked at $13.8M in Q3 2021. 157 funds tracked by Wall St. Rank hold CLDX as of Q2 2022.

Ghost Tree Capital reported no remaining Celldex Therapeutics position as of Q2 2022 after selling out during the quarter.
Ghost Tree Capital sold 300,000 Celldex Therapeutics shares in Q2 2022, an estimated $8.71M.
Ghost Tree Capital first reported a position in Celldex Therapeutics in Q1 2021 and held it in 5 quarters.
Ghost Tree Capital's Celldex Therapeutics position peaked at $13.8M in Q3 2021.
157 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2022.

Based on Ghost Tree Capital's 13F filing for Q2 2022, filed 15 Aug 2022.